| Previous Close | 57.80 |
| Open | 57.95 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 56.81 - 58.65 |
| 52 Week Range | 16.61 - 59.50 |
| Volume | 449,539 |
| Avg. Volume | 601,433 |
| Market Cap | 2.02B |
| Beta | 0.58 |
| PE Ratio (TTM) | -17.42 |
| EPS (TTM) | -3.31 |
| Earnings Date | Aug 1, 2017 - Aug 7, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.13 |
- Business Wire•5 days ago
Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results
Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™....
- Zacks•2 months ago
Can The Uptrend Continue for Aerie Pharmaceuticals (AERI)?
Investors certainly have to be happy with Aerie Pharmaceuticals Inc (AERI) and its short term performance
